In China, the price trend of Olmesartan Medoxomil API followed the upward price trajectory since September 2022 and continued to increase further till the end of November 2022. Before the downtrend approaches during the current month, Olmesartan Medoxomil API prices rose a total of 1.9% in November 2022 due to a shortage of inventories among domestic manufacturers. However, the National Bureau of Statistics predicts that China's manufacturing Purchasing Manager's Index (PMI) was down to 48.0 in November from 49.2 in October but still stayed in the contractionary territory. Therefore, the economic growth of China's manufacturing sector remained weak as COVID-19 containment measures continued to weigh on the industry.

During December 2022, China's Olmesartan Medoxomil API markets have recently mixed as demand may remain soft despite a further relaxation in the country's COVID-19 curbs. Even though late on 7 December, the Chinese government announced various measures to optimize its COVID-19 policy. Thus, prices of Olmesartan Medoxomil API started to decline with the onset of December. Manufacturers frequently link the current decline to the impact of COVID-19 restrictions on operations. Also, end-user demand from the overseas market remains weak as Christmas Holiday approaches in some regions. Nevertheless, a consensus among the market players is that robust demand will take time to return. According to the ChemAnalyst analysis, Olmesartan Medoxomil API prices are expected to reduce by more than 2% towards the end of the year as the market situation will be dull.

In the meantime, Europe and the U.S. followed a similar pricing trend to China. However, German and U.S. traders had inadequate inventories of Olmesartan Medoxomil API in November due to limited imports from China amid Covid-19 protocols. At the same time, surging demand for Olmesartan Medoxomil API from the end-user pharmaceutical industry resulted in high prices. However, the ease in supply chain disruption from the first week of December has given Olmesartan Medoxomil API producers some respite in the wake of recent crashing demand. Additionally, the smoother product flow from exporting countries could further destabilize market fundamentals rather than provide balance to the Olmesartan Medoxomil API market in December. As new orders in Europe have subsided as the Christmas season draws near, this has allowed traders to catch up with backlogs, smoothing out extended lead times and allowing congested bottlenecks to dissipate. All these factors cause the decrease in Olmesartan Medoxomil API in Germany and USA.

Therefore, the Global Olmesartan Medoxomil API prices may shift upward in the first quarter of 2023 after the Christmas holidays end, as markets will reopen and end-user demand will likely increase.